| 0.8674 -0.143 (-14.12%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.37 |
1-year : | 1.6 |
| Resists | First : | 1.17 |
Second : | 1.37 |
| Pivot price | 1.11 |
|||
| Supports | First : | 0.86 |
Second : | 0.71 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 1.14 |
| MA(100) : | 1.08  |
MA(250) : | 1.14 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 24.9 |
| RSI | RSI(14): 31.2 |
|||
| 52-week | High : | 3.25 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KAPA ] has closed below the lower bollinger band by 22.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ KAPA ] is to continue within current trading range. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.12 |
| Low: | 0.98 - 0.99 | 0.99 - 1 |
| Close: | 1 - 1.01 | 1.01 - 1.02 |
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Tue, 04 Nov 2025
Kairos Pharma (NYSE American: KAPA) posts PFS 13.7 in ENV105; no Grade 4/5 toxicities - Stock Titan
Mon, 20 Oct 2025
Analyst D. Boral Capital Maintains Buy Rating on Kairos Pharma (KAPA) | KAPA Stock News - GuruFocus
Wed, 15 Oct 2025
Kairos Pharma Approves RSUs and Cash Bonuses - TipRanks
Tue, 14 Oct 2025
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO - AlphaStreet
Tue, 07 Oct 2025
Kairos Pharma stock rises after selection for ESMO Congress presentation - Investing.com
Thu, 18 Sep 2025
Kairos Pharma Reports Positive Phase 2 Trial Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|